Overview of Erector

Property	Description
Active ingredient	Sildenafil (as Sildenafil Citrate)
Form	Oral tablet (Film-coated)
Pharmacological class	Phosphodiesterase Type 5 (PDE5) Inhibitor
Common use	Vascular response support; improved local blood flow
Origin	Synthetic compound

What Type of Medicine is Erector?

Erector is a specific medicinal product defined by its active ingredient, Sildenafil, and classified as a highly selective Phosphodiesterase Type 5 (PDE5) Inhibitor. This classification places it within a specialized group of synthetic oral agents that modulate vascular processes. Erector is provided as a prescription-only medicine (Rx), intended for use under the guidance of a healthcare professional. The drug is supplied as an oral tablet, typically film-coated, designed for systemic absorption via the oral route of administration. Its pharmacological type is determined by its specific effect on the PDE5 enzyme, differentiating its action from broader, non-selective cardiovascular agents.

What is the General Purpose of Erector (Sildenafil)?

The general purpose of Erector is to support and enhance the body's natural processes of vascular relaxation and blood flow regulation in specific areas. The underlying principle is to facilitate selective smooth muscle relaxation by temporarily blocking the PDE5 enzyme, which leads to increased local blood circulation and improves the body's vascular response. This mechanism is primarily utilized to help achieve a desired physiological response in conditions requiring enhanced local blood flow, such as in instances of sexual function difficulties where vascular support is needed, or for conditions related to elevated pressure in the pulmonary circulation.

Is Erector a Single Compound or Combination Product?

Erector is consistently provided as a single-ingredient product, or monotherapy, containing only the active pharmaceutical ingredient Sildenafil (as Sildenafil Citrate) alongside inactive solid excipients. Its composition focuses solely on the therapeutic action of Sildenafil, avoiding combination with other active drugs. This single-compound formulation is clinically recognized for providing a predictable and targeted mechanism of action. The design as an oral tablet emphasizes the intended route of administration and provides a convenient, non-invasive means for the patient to receive the precise, defined dose of the synthetic compound.

What side effects are possible with Erector?

Possible side effects and safety information

The official safety profile for Erector (Sildenafil) is structured by government regulatory documents, classifying potential adverse reactions by frequency and physiological system. This classification separates expected, common effects from rare, but serious, safety concerns.

Classification	Examples of Officially Documented Adverse Reactions
Very Common (ge 1/10)	Headache
Common (ge 1/100 to <1/10)	Flushing, Dyspepsia (Indigestion), Abnormal vision (including color distortion), Nasal congestion, Dizziness, Nausea

Side effects are documented across various System-Organ Classes, including Nervous System, Eye, Vascular, Gastrointestinal, and Musculoskeletal disorders. The incidence of adverse reactions in elderly patients (ge 65 years) may be higher due to increased systemic exposure, as noted in the regulatory findings.

Serious Adverse Reactions have been reported, primarily from post-marketing surveillance. These include Priapism (a prolonged erection lasting over four hours), sudden loss of vision (Non-arteritic Anterior Ischaemic Optic Neuropathy or NAION), and sudden decrease or loss of hearing. Serious cardiovascular events, such as myocardial infarction or stroke, have also been reported in proximity to use.

Safety-Related Restrictions delineate specific patient constraints. The medicine is contraindicated for use with any form of organic nitrates or nitric oxide donors due to the risk of severe hypotension. Additionally, the safety of the medicine is not established and use is restricted in patients with severe hepatic impairment, recent history of stroke or myocardial infarction (within six months), or resting hypotension. The risk of specific cardiovascular events is noted as occurring during or shortly after sexual activity, or shortly after use without sexual activity.

Overdose and Emergency Response

Overdose of Erector (Sildenafil) is officially documented as producing adverse events consistent with lower doses but occurring with increased rates and severity. Manifestations may include severe headache, exaggerated flushing, and significant hypotension (low blood pressure), which can lead to syncope (fainting). High exposures may also increase the risk of severe post-marketing cardiovascular events.

Regulatory guidance specifies several situations that mandate immediate medical assistance. This is strictly required for an erection that persists longer than four hours (priapism), as this outcome carries a serious risk of penile tissue damage and potential permanent loss of potency. Urgent medical consultation is also required for any sudden loss of vision (a potential sign of Non-Arteritic Anterior Ischemic Optic Neuropathy) or sudden decrease or loss of hearing.

Formal overdose management described in regulatory documents consists of symptomatic and supportive treatment. There is no specific antidote documented. Regulatory information clarifies that due to the compound's extensive plasma protein binding, standard interventions like renal dialysis are not expected to accelerate clearance of the active ingredient. Furthermore, reduced clearance is noted in patients with hepatic impairment, suggesting a potential for higher drug exposure in this population.

Therapeutic Uses of Erector

What Erector Treats: Main Uses and Benefits

Erector (Sildenafil) is commonly used to provide targeted therapeutic support across distinct physiological domains, is applied in addressing specific symptom clusters, and may assist with maintaining functional capacity. The medication is considered relevant for managing symptoms in two key conditions: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

For men with ED, the medication is applied in scenarios involving symptoms that create noticeable physiological strain, particularly the inability to achieve or sustain adequate rigidity. This assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

“The primary benefit is supportive relief when symptoms interfere with routine activities.”

Erector is also considered relevant in conditions characterized by periods of heightened symptoms, such as PAH, a condition characterized by elevated blood pressure in the lung arteries. In this context, it helps ease the resultant symptoms of cardiopulmonary strain, such as unusual shortness of breath and fatigue during exertion, by providing supportive relief when symptoms create noticeable physiological strain.

Quick Fact: Relief for Inadequate Penile Rigidity
This medication is commonly used to help with addressing symptoms that interfere with daily functioning and is relevant for easing the functional strain associated with difficulties in sustaining a satisfactory erection.

Regulatory References

NIH MedlinePlus overview of Sildenafil

Eligibility and Restrictions for Use

Eligibility to Use Erector (Alprostadil Injectable) — Official Regulatory Information

Official regulatory documents strictly define the population eligible to use this medication, based primarily on sex, age, and pre-existing medical conditions that relate to potential risks.

Who Can Use It

The medication is indicated for use exclusively in adult men (males), typically 18 years of age and older, for the treatment of erectile dysfunction.

Who Cannot Use It (Contraindicated Populations)

Use is formally contraindicated (prohibited) in several specific populations, including:

Women and Children: The drug is not indicated for and must not be used by women or children.
Hypersensitivity: Individuals with a known hypersensitivity or allergy to the drug or any of its components.
Conditions Predisposing to Priapism: Men with hematologic conditions that increase the risk of a prolonged erection (priapism), such as sickle cell anemia (or trait), multiple myeloma, or leukemia.
Penile Fibrotic Conditions: Men with certain structural or anatomical deformities of the penis, including Peyronie's disease, cavernosal fibrosis, or penile angulation.
Penile Implants: Men who have a surgically implanted penile prosthesis.

Restrictions on Use

Use may be inadvisable or restricted for men whose underlying cardiovascular status makes sexual activity unsafe. Furthermore, use is not recommended in combination with other intracavernosally injected vasoactive agents, as safety and efficacy have not been established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Erector (Sildenafil) engages in officially documented interaction patterns primarily classified as pharmacodynamic (additive effects) and pharmacokinetic (metabolic alteration) based on regulatory information.

Prohibited Combinations

The co-administration of Erector with certain medicines is strictly contraindicated by regulatory authorities. This prohibition is due to the risk of severe, life-threatening hypotension, an additive pharmacodynamic effect.

Interaction Type	Interacting Substances	Restriction
Additive Vasodilation	Organic Nitrates (e.g., Nitroglycerin)	Contraindicated
Additive Vasodilation	Guanylate Cyclase Stimulators (e.g., Riociguat)	Contraindicated

Pharmacokinetic Interactions

Sildenafil is largely cleared via the hepatic enzyme CYP3A4, making its plasma levels susceptible to alteration by metabolic inhibitors and inducers. CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) cause a substantial increase in sildenafil plasma concentrations due to reduced metabolic clearance. Conversely, CYP3A4 Inducers may reduce sildenafil plasma levels. When co-administering with a potent inhibitor like Ritonavir, a specific regulatory constraint limits the maximum single dose within a 48-hour period.

Pharmacodynamic and Food Interactions

Co-administration with Alpha-Blockers or other Anti-Hypertensives may cause additive blood pressure lowering effects. Symptomatic hypotension is officially documented as most likely to occur within four hours of simultaneous dosing. The absorption rate of Erector is officially delayed by a high-fat meal, extending the time to reach maximum plasma concentration. Furthermore, the clearance of Sildenafil is reduced in individuals with severe renal or hepatic impairment, resulting in higher documented systemic exposure.

Mechanism of Action

Erector (sildenafil) functions as a selective competitive inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). This enzyme is present in various tissues, including the smooth muscle of the corpus cavernosum of the penis and the pulmonary vasculature.

Under specific local signaling, nitric oxide (NO) is released, which activates guanylate cyclase. This activation elevates intracellular cGMP levels. Normally, PDE5 rapidly hydrolyzes cGMP, terminating this signal. By inhibiting PDE5, Erector prevents this degradation, leading to the accumulation of cGMP within the smooth muscle cells of the targeted tissues. The sustained increase in cGMP activates protein kinase G, which initiates a cascade of phosphorylations. Downstream consequences include the deactivation of myosin light chain kinase and a reduction in intracellular calcium concentration. This dual effect mediates smooth muscle relaxation and resultant vasodilation, facilitating increased blood flow into the specific vascular beds, thereby modulating systemic hemodynamics.

Dosage and Administration Information

Administration Scope

Instruction Entity	Administration Guideline
Route of administration	The primary route is Oral (tablet or suspension). The Intravenous (IV) injection route is reserved for specific clinical settings in the case of Pulmonary Arterial Hypertension (PAH).
Dosing schedule	Intermittent Use: The common starting dose is 50 mg, adjustable from 25 mg to 100 mg. Continuous Use (PAH): Standard oral dose of 20 mg.
Timing in relation to meals	The tablet may be taken with or without food. Administration with a high-fat meal may lead to a delay in the onset of action for intermittent use.
Preparation requirements	The oral suspension must be reconstituted with water before initial use and shaken vigorously before each subsequent dose.
Age-group administration rules	An initial dose of 25 mg should be considered for older adults (65 years and over) for the intermittent regimen.

Instruction Classifications

Classification	Description
Administration method type	Oral (ingestion of tablet or suspension) and Intravenous (bolus injection) administration.
Frequency pattern	Intermittent (as-needed, max once daily) or Scheduled Continuous (three times daily).
Use-context constraints	Intermittent use requires administration within a 30-minute to 4-hour window prior to activity.

Connection to the Overall Use Protocol

The established instructions maintain a strict bifurcation of use protocols, separating the intermittent, on-demand administration (defined by a single maximum dose and a timing window) from the continuous, scheduled administration (defined by a fixed low dose taken three times daily). This dichotomy in administration scope, dosage, and frequency separates the procedural requirements for the different applications of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Pharmacological Studies and Mechanism

Research has explored the compound's characteristics as a phosphodiesterase type 5 (PDE5) inhibitor. Studies suggest that the molecule's action may prevent the degradation of a key messenger chemical, cyclic guanosine monophosphate (cGMP), which is crucial for smooth muscle relaxation and vasodilation. This effect is thought to be dose-dependent and necessitates prior sexual stimulation to initiate the physiological pathway.

Pharmacokinetic data indicate the compound is rapidly absorbed, typically reaching maximum concentration within one hour of administration, though absorption may be delayed when taken with a high-fat meal. The primary compound and its active metabolite are predominantly metabolized by the liver.

Efficacy Research in Erectile Dysfunction (ED)

Numerous placebo-controlled clinical trials have evaluated the compound in adult men experiencing erectile dysfunction of various etiologies, including organic and psychogenic causes. Research focused on measuring endpoints such as the International Index of Erectile Function (IIEF) domain scores and the reported frequency of successful intercourse attempts.

Improvement Rates: In pooled analyses of multiple studies, participants receiving the compound reported higher rates of improved erections compared to those receiving placebo.
Specific Subgroups: Studies have explored the compound's use in specific patient populations, including men with ED secondary to complications such as diabetes mellitus and those who have undergone radical prostatectomy.

Tolerability and Long-Term Data

Studies that assessed the compound's use over periods up to four years have examined its long-term tolerability profile. In clinical trials, the compound was generally associated with a favorable tolerability profile, with common reported adverse events being mild and transient, such as headache and flushing. Dose adjustments (e.g., 25 mg, 50 mg, or 100 mg) based on individual response and tolerability are a key feature of its clinical evaluation.

Research has also investigated the safety profile of the compound when combined with certain medications, noting that caution is required due to the potential for interaction with antihypertensive or anti-anginal agents.

Frequently Asked Questions (FAQ)

Common questions about Erector (FAQ)

Q: Is Erector the same as other medicines for the same condition?

Official documents describe Erector as Sildenafil, which is the active ingredient. It belongs to a specific group of medicines known as phosphodiesterase type 5 (PDE5) inhibitors. While it treats conditions similar to other medicines, its mechanism and chemical structure are specific to Sildenafil.

Q: Is Erector intended for long-term use?

Regulatory documents define separate administration protocols for its use, including options for continuous administration for certain conditions such as Pulmonary Arterial Hypertension (PAH). The medicine can also be used on an intermittent, as-needed basis. Studies have examined its tolerability profile over several years.

Q: Can Erector interact with common vitamins or supplements?

The medicine is primarily cleared from the body by the CYP3A4 liver enzyme. This means its concentration can be affected by other substances, including certain supplements, that interact with this enzyme. Official documents note the importance of providing a healthcare provider with a complete list of all concurrent medications and supplements for review.

Q: Why do some people need to avoid taking Erector?

Official regulatory materials list specific medical conditions and co-administered medicines that strictly prohibit the use of Erector, a status known as a contraindication. For example, use is restricted if a person is taking any form of organic nitrates or has a severe condition like hepatic impairment. These restrictions are in place due to the risk of serious side effects.

Q: Does taking Erector mean I will have to change my diet?

Official administration guidelines state the tablet may be taken with or without food. However, regulatory findings note that consuming the medicine with a high-fat meal may delay how quickly the drug starts to work. There are no mandatory dietary changes described in the official instructions.

Q: Is there a generic version of Erector available?

The active ingredient in Erector is Sildenafil. Regulatory sources use this chemical name, and the active ingredient Sildenafil is used in products marketed as generic versions of the medicine.

Q: Can people with kidney problems use Erector?

Official findings note that the clearance of the medicine is reduced in individuals with severe renal impairment (severe kidney problems). This reduction in clearance is associated with the potential for higher systemic exposure to the medicine.

Q: Can I take Erector if I am taking an antidepressant?

Since Erector is cleared by the CYP3A4 enzyme, some medicines, including certain antidepressants, may affect this enzyme and alter the level of Erector in the body. Official documents note that a healthcare provider should review all current medications before the medicine is used.

Q: How long does the effect of Erector typically last?

Pharmacokinetic data described in official documents indicate the medicine's effects are temporary. The terminal half-life—the time it takes for half of the drug to be cleared from the body—for the active compound is approximately 4 hours.

Q: What if I miss a scheduled time to take Erector?

For the continuous, scheduled regimen (such as for PAH), official patient information describes specific procedures to follow if a dose is missed.

Q: Are there any common foods or drinks that interact with Erector?

Official regulatory warnings specifically mention the use of alcohol. The simultaneous consumption of alcohol may increase the potential for the low blood pressure effects associated with the medicine.

Q: Does Erector affect blood pressure?

The medicine's mechanism of action involves vasodilation, which is the relaxation of blood vessels. This action facilitates increased blood flow. The drug is officially approved to treat high blood pressure in the lungs, known as Pulmonary Arterial Hypertension (PAH).

Q: Is Erector a controlled substance?

Regulatory scheduling lists in many major jurisdictions do not classify the active ingredient, Sildenafil, as a controlled substance.

Q: Can Erector be used by women?

The medicine has officially approved uses for both men and women. Specifically, it is approved for the treatment of Pulmonary Arterial Hypertension (PAH) in both genders.

Q: Does Erector change the body's natural processes permanently?

According to the official mechanism of action, the medicine functions as a selective competitive inhibitor of an enzyme. This action is temporary and is described as ceasing once the medicine is cleared from the body.

Q: Do studies show a difference in effect based on age or gender?

Clinical studies have included analyses based on age, indicating that clinical efficacy results were broadly comparable across age subgroups examined in the studies. Official information also notes that older adults may have increased systemic exposure to the medicine.

Q: Is Erector available over the counter in some countries?

Regulatory decisions in some countries have allowed for the reclassification of the medicine, or versions containing the active ingredient, to be sold without a prescription from a pharmacy.

Q: What is the shelf life of Erector?

Official stability data define the maximum time the product maintains its effectiveness, known as the shelf life. This information is reflected in the specific expiration dates applied to the medicine's packaging.

Q: Are there different strengths of Erector available?

Yes, official labeling defines that the medicine is available in multiple dosage strengths, such as 20 mg, 25 mg, 50 mg, and 100 mg tablets.

Q: Why are there warnings about interactions with certain heart medicines?

Official warnings describe that combining Erector with organic nitrates or guanylate cyclase stimulators is strictly prohibited due to the risk of a dangerous additive effect. This combination can lead to severe, life-threatening low blood pressure (hypotension).

Q: What kind of monitoring is needed while taking Erector?

Official documents state that evaluation for underlying cardiovascular status is a consideration before initiating or resuming any sexual activity after starting the medicine.

Q: Can Erector be crushed or split?

Regulatory information describes that the oral suspension form of the medicine requires reconstitution (mixing with water) and shaking before use. It does not describe any scoring or instruction for splitting or crushing the tablet form.

Q: What are the reasons Erector might not work for some people?

Clinical study results describe that the medicine does not work for all participants. Official documents indicate that efficacy rates are often tied to the specific underlying cause and severity of the condition being treated.

Q: Do regulatory agencies classify Erector as high-risk?

Regulatory documents detail the medicine’s potential safety profile by classifying a range of documented side effects, from common reactions to rare, serious adverse events.

Q: Is it normal to not notice the effects of Erector right away?

Yes, official findings note that absorption is not immediate. The concentration of the drug typically reaches its maximum level within one hour of administration, with a potential delay if taken with a high-fat meal.

How should Erector be stored and disposed of?

Official Storage and Disposal Requirements

Sildenafil tablets (Erector) must be stored strictly according to regulatory mandates to maintain stability. The official requirement is to keep the medication at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), while protecting it from excess heat and moisture. The product should remain in its original container and be kept tightly closed and away from direct light. A mandatory safety instruction is to always store the medication out of the sight and reach of children.

For disposal, unused or expired Sildenafil should be managed according to local regulations, often prioritizing drug take-back programs. If no take-back option is available, the tablets must be removed from the container, mixed with an undesirable substance, sealed in a bag, and then placed in the household trash, as specified by health authorities.

Erector